ApicHope Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers pediatric medicines; chronic disease drugs; active pharmaceutical ingredients and formulations; and specialty traditional Chinese medicines. It is also involved in scientific research and technical services; wholesale an...
ApicHope Pharmaceutical Group reported revenue of 1.45 billion CNY for fiscal year 2024, down 42.1% from fiscal year 2023, and net income of -540.04 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 206.84 million CNY, down 28.6% from a year before. Its largest business segment, Pharmaceutical Manufacturing, brought in 96% of segment revenue in fiscal year 2025.
Figures from company filings; latest fiscal year ended December 31, 2024.
No profile data available.